Fig. 2: The inhibitory action of S11 on HDAC, P-gp, and cisplatin-resistant NSCLC cells. | Cell Death & Disease

Fig. 2: The inhibitory action of S11 on HDAC, P-gp, and cisplatin-resistant NSCLC cells.

From: Targeting HDAC/OAZ1 axis with a novel inhibitor effectively reverses cisplatin resistance in non-small cell lung cancer

Fig. 2: The inhibitory action of S11 on HDAC, P-gp, and cisplatin-resistant NSCLC cells.

a HDAC activity was detected by microplate reader in S11- and DMSO-treated A549 and A549/CDDP cells. PXD101 was used as positive control. b The P-gp ATPase activity in vitro was measured by Pgp Glo assay system. Elacridar was used as positive control. c The cell viability of A549, A549/CDDP, NCI-H460, NCI-H460/CDDP, NCI-H1299, and NCI-H1299/CDDP cells after treatment with different concentrations of S11 and CDDP for 48 h

Back to article page